Venous thromboembolism UK Medical PG Practice Questions and MCQs
Practice UK Medical PG questions for Venous thromboembolism. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Venous thromboembolism UK Medical PG Question 1: A 52-year-old woman presents with progressive dysphagia and weight loss. She has tight skin on her hands and face. ANA shows nucleolar pattern. What is the most concerning systemic complication?
- A. Renal crisis
- B. Pulmonary hypertension (Correct Answer)
- C. Cardiac arrhythmias
- D. Digital ulceration
- E. Arthritis
Venous thromboembolism Explanation: ***Pulmonary hypertension*** - This patient's presentation with **dysphagia**, **tight skin on hands and face**, and **nucleolar ANA pattern** strongly suggests systemic sclerosis, particularly the limited cutaneous form. - **Pulmonary hypertension** is a common and severe life-threatening complication of systemic sclerosis, especially in the limited cutaneous subtype, requiring vigilant screening and management. *Renal crisis* - **Scleroderma renal crisis** is a severe complication, but it is more frequently associated with **diffuse cutaneous systemic sclerosis** and anti-RNA polymerase III antibodies. - It presents with **malignant hypertension** and rapidly progressive renal failure, which is not suggested as the primary concern here. *Cardiac arrhythmias* - While **cardiac involvement** like myocardial fibrosis and pericarditis can occur in systemic sclerosis, **cardiac arrhythmias** are typically not the most concerning life-threatening systemic complication. - They are less common as a primary life-threatening event compared to **pulmonary hypertension**. *Digital ulceration* - **Digital ulceration** is a common localized vascular manifestation of systemic sclerosis due to **Raynaud's phenomenon** and small vessel disease. - Though it can cause pain, infection, and significant morbidity, it is not considered the most concerning **systemic life-threatening complication**. *Arthritis* - **Arthritis** or arthralgia can occur in systemic sclerosis, often affecting small joints and typically **non-erosive**. - While it contributes to discomfort, it is not considered a major **life-threatening systemic complication** compared to visceral organ involvement like pulmonary hypertension.
Venous thromboembolism UK Medical PG Question 2: A 42-year-old woman presents with fatigue, muscle aches, and widespread pain. She has multiple tender points but normal inflammatory markers. Sleep is poor. What is the most appropriate initial treatment?
- A. NSAIDs
- B. Prednisolone
- C. Pregabalin (Correct Answer)
- D. Methotrexate
- E. Physiotherapy alone
Venous thromboembolism Explanation: ***Pregabalin***
- **Pregabalin** is a **gabapentinoid** drug that modulates voltage-gated calcium channels, decreasing the release of excitatory neurotransmitters involved in central pain sensitization characteristic of **fibromyalgia**.
- It is one of the FDA-approved medications (along with duloxetine and milnacipran) specifically recommended for managing the **widespread pain** and associated symptoms like **poor sleep** in fibromyalgia.
*NSAIDs*
- Non-steroidal anti-inflammatory drugs (NSAIDs) target inflammatory pain, which is generally absent in **fibromyalgia** as evidenced by **normal inflammatory markers**.
- NSAIDs are usually **ineffective** in treating the centralized pain and hyperalgesia seen in this condition, making them a poor choice for monotherapy.
*Prednisolone*
- **Prednisolone** is a powerful corticosteroid used for conditions driven by **inflammation** (e.g., active arthritis or vasculitis).
- The patient has normal inflammatory markers and a clinical presentation consistent with a non-inflammatory central pain syndrome, making steroids **inappropriate** and potentially harmful.
*Methotrexate*
- **Methotrexate** is a **Disease-Modifying Anti-Rheumatic Drug (DMARD)** indicated for managing autoimmune inflammatory diseases like **Rheumatoid Arthritis** or **Psoriatic Arthritis**.
- Since the patient does not show evidence of an inflammatory or autoimmune joint disease, this immunosuppressant drug treatment is **not warranted**.
*Physiotherapy alone*
- While non-pharmacological therapies like **aerobic exercise** and **Cognitive Behavioral Therapy (CBT)** are essential long-term components, they are often insufficient alone to manage severe initial symptoms, particularly **poor sleep** and disabling pain.
- Initial treatment typically requires a combination of pharmacological agents (like **Pregabalin**) combined with supportive non-pharmacological management for optimal symptom control.
Venous thromboembolism UK Medical PG Question 3: A 52-year-old man presents with progressive dysphagia and weight loss. He has tight skin on his hands and Raynaud's phenomenon. What is the most likely esophageal abnormality?
- A. Esophageal carcinoma
- B. Achalasia
- C. Esophageal dysmotility (Correct Answer)
- D. Peptic stricture
- E. Eosinophilic esophagitis
Venous thromboembolism Explanation: ***Esophageal dysmotility***- The combination of **tight skin (scleroderma)** and **Raynaud's phenomenon** is characteristic of **Systemic Sclerosis**, which causes atrophy and fibrosis of smooth muscle in the distal two-thirds of the esophagus.- This loss of smooth muscle function leads to decreased peristalsis (dysmotility) and, crucially, incompetence of the **lower esophageal sphincter (LES)**, causing severe GERD and the resulting dysphagia.*Esophageal carcinoma*- While progressive **dysphagia** and **weight loss** are concerns for malignancy, the patient's systemic features (**tight skin**, **Raynaud's**) strongly suggest a connective tissue disorder as the etiology.- Carcinoma often occurs in the context of significant risk factors (e.g., smoking, alcohol, HPV) and typically does not present with the classic dermatologic or peripheral vascular signs of Scleroderma.*Achalasia*- Achalasia involves impaired relaxation of the **LES** and aperistalsis, but it is a primary esophageal motility disorder and lacks the systemic features (Raynaud's, sclerodactyly) seen in this patient.- Dysphagia in achalasia tends to be prominent for both **liquids and solids** from the start, often without significant GERD symptoms.*Peptic stricture*- A **peptic stricture** is a *consequence* of chronic acid exposure resulting from the incompetent LES caused by Scleroderma-related esophageal dysmotility.- While a stricture may eventually explain the severe dysphagia, the primary diagnostic link between the systemic symptoms and the esophageal pathology is the **underlying smooth muscle failure** (dysmotility).*Eosinophilic esophagitis*- This condition is typically associated with **atopic disorders** (allergies, asthma) and presents histologically with excessive **eosinophil infiltration**.- It typically causes dysphagia, often for solids, and sometimes **food impaction**, but it is not linked to generalized fibrosis or vascular changes like those causing tight skin and Raynaud's phenomenon.
Venous thromboembolism UK Medical PG Question 4: A 46-year-old woman presents with fatigue, muscle weakness, and purple discoloration around her eyes. She has Gottron's papules over her knuckles. CK is 3800 U/L. What is the most important investigation?
- A. EMG
- B. Muscle biopsy
- C. CT chest/abdomen/pelvis (Correct Answer)
- D. Myositis antibodies
- E. Echocardiogram
Venous thromboembolism Explanation: ***CT chest/abdomen/pelvis***
- The most important investigation in a patient with new-onset **dermatomyositis**, especially in a middle-aged or older individual, is a thorough screening for **underlying malignancy**.
- Approximately 15-30% of patients with dermatomyositis have an associated cancer, making **malignancy screening** crucial for prognosis and management.
*EMG*
- While an **EMG** can show **myopathic changes** (e.g., fibrillation potentials, small-amplitude polyphasic motor unit potentials) consistent with inflammatory myopathy, it primarily confirms muscle involvement.
- Confirming muscle involvement is important diagnostically, but ruling out an **associated malignancy** takes precedence given its significant impact on patient survival.
*Muscle biopsy*
- A **muscle biopsy** is often considered the gold standard for diagnosing inflammatory myopathies, showing characteristic **perifascicular atrophy** and inflammation in dermatomyositis.
- However, while confirming the diagnosis, the immediate priority in this clinical picture is to identify or exclude a potentially life-threatening **underlying malignancy**.
*Myositis antibodies*
- **Myositis-specific antibodies** (e.g., anti-Jo-1, anti-MDA5, anti-TIF1γ) are useful for classifying inflammatory myopathies, predicting disease course, and assessing specific associations (e.g., malignancy risk with anti-TIF1γ).
- While helpful diagnostically and for risk stratification, these antibodies do not directly screen for an **underlying malignancy**; imaging is required for that purpose.
*Echocardiogram*
- An **echocardiogram** assesses cardiac function and can detect myocardial involvement, which can occur in inflammatory myopathies (e.g., myocarditis, heart failure).
- While cardiac complications can arise, they are not the *most important initial investigation* when the clinical picture strongly suggests **dermatomyositis** with its significant risk of an **underlying malignancy**.
Venous thromboembolism UK Medical PG Question 5: A 48-year-old man presents with progressive muscle weakness affecting proximal muscles. CK is elevated at 3200 U/L. Muscle biopsy shows inflammatory infiltrates. What is the cancer screening recommendation?
- A. No screening needed (Correct Answer)
- B. Chest X-ray only
- C. CT chest/abdomen/pelvis
- D. Colonoscopy only
- E. PSA testing only
Venous thromboembolism Explanation: ***No screening needed***- The clinical presentation of **progressive proximal muscle weakness**, elevated **CK**, and **inflammatory infiltrates** on muscle biopsy is consistent with **polymyositis**.- Unlike **dermatomyositis**, which has a strong association with occult malignancies, **polymyositis** is generally not associated with an increased risk of cancer, therefore **routine cancer screening** is not indicated. *Chest X-ray only*- A **chest X-ray** is a limited screening tool and would be insufficient to detect a wide range of potential malignancies associated with paraneoplastic syndromes.- It would miss cancers in other vital organs, making it an inadequate approach if malignancy were suspected. *CT chest/abdomen/pelvis*- This extensive imaging is typically recommended for patients with **dermatomyositis** due to its strong association with various occult malignancies.- In the absence of dermatomyositis-specific features (e.g., characteristic skin rashes) or other malignancy risk factors, such broad screening is not indicated for **polymyositis**. *Colonoscopy only*- While gastrointestinal malignancies can be associated with paraneoplastic syndromes, performing **colonoscopy** alone is insufficient for comprehensive cancer screening.- This approach would overlook other common cancer sites linked to inflammatory myopathies, such as lung, breast, or ovarian cancers. *PSA testing only*- **PSA testing** is specific for prostate cancer screening and would be part of a more comprehensive workup, not the sole screening measure for malignancy.- Focusing solely on prostate cancer would miss other potential malignancies that might be associated with paraneoplastic syndromes in other forms of inflammatory myopathies.
Venous thromboembolism UK Medical PG Question 6: A 41-year-old woman presents with recurrent miscarriages and arterial thrombosis. She has positive lupus anticoagulant and anticardiolipin antibodies. What is the most appropriate long-term treatment?
- A. Aspirin alone
- B. Warfarin (INR 2-3) (Correct Answer)
- C. Clopidogrel
- D. LMWH
- E. No treatment
Venous thromboembolism Explanation: ***Warfarin (INR 2-3)***- For patients with **Antiphospholipid Syndrome (APS)** who have experienced a confirmed thrombotic event (arterial or venous), **vitamin K antagonists** like **Warfarin** are the mainstay of long-term secondary prevention.- Given the history of **arterial thrombosis**, a target **International Normalized Ratio (INR)** of 2.0 to 3.0 is typically recommended, as this range effectively reduces the risk of recurrent thrombotic events in APS.*Aspirin alone*- Aspirin is generally reserved for primary prophylaxis in high-risk, asymptomatic carriers of antiphospholipid antibodies or often used as **adjuvant therapy**, but it is insufficient as monotherapy following a definite **arterial thrombotic event** in APS.- The risk of recurrence after thrombosis in APS is high, necessitating **full anticoagulation**, which **Aspirin** (an antiplatelet agent) cannot provide effectively.*Clopidogrel*- Clopidogrel is an antiplatelet agent often used for high-risk cardiovascular conditions but is not the standard first-line agent for the prevention of recurrent **thrombosis** associated with APS, which requires potent **anticoagulation**.- Like aspirin, **antiplatelet therapy** alone does not adequately address the highly procoagulant nature of circulating **lupus anticoagulant** and other antiphospholipid antibodies following a thrombotic episode.*LMWH*- **Low Molecular Weight Heparin (LMWH)** is the preferred treatment for APS patients during **pregnancy** (for fetal and maternal health) or during acute thrombotic events.- While effective, LMWH is impractical for **lifelong secondary prevention** outside of pregnancy due to the requirement for daily subcutaneous injections.*No treatment*- This patient has classic features of **definite Antiphospholipid Syndrome (APS)**, including required laboratory criteria and clinical thrombotic events (arterial thrombosis and pregnancy morbidity).- Untreated patients with a history of **APS-related thrombosis** face a very high risk of **recurrent life-threatening events**, making therapy mandatory.
Venous thromboembolism UK Medical PG Question 7: A 38-year-old woman presents with fatigue, joint pain, and photosensitive rash. ANA is positive 1:640, anti-dsDNA is positive, and complement levels are low. Urinalysis shows proteinuria and RBC casts. What is the most appropriate initial treatment?
- A. NSAIDs
- B. Hydroxychloroquine
- C. High-dose prednisolone (Correct Answer)
- D. Methotrexate
- E. Rituximab
Venous thromboembolism Explanation: ***High-dose prednisolone***- This patient presents with features of **severe active Systemic Lupus Erythematosus (SLE)**, confirmed by high-titer ANA, positive anti-dsDNA, low complement, and active **Lupus Nephritis** (proteinuria, RBC casts).- **High-dose glucocorticoids** (e.g., prednisolone or methylprednisolone pulses) are the cornerstone initial treatment to rapidly induce remission and prevent irreversible damage in severe, active organ-threatening SLE.*NSAIDs*- **NSAIDs** are reserved for mild disease manifestations, typically musculoskeletal symptoms such as arthralgia or non-erosive arthritis, without major organ involvement.- They are generally avoided in active severe **Lupus Nephritis** as they carry a risk of exacerbating renal impairment or non-steroidal induced nephropathy.*Hydroxychloroquine*- **Hydroxychloroquine** is foundational maintenance therapy for almost all SLE patients, reducing flares, preventing damage accrual, and improving survival.- It acts slowly and is **insufficient as monotherapy** to control acute, severe, organ-threatening disease activity like active nephritis, which requires immediate, potent immunosuppression.*Methotrexate*- **Methotrexate** is typically considered for non-organ-threatening manifestations of SLE, such as refractory arthritis or treatment-resistant rash, when hydroxychloroquine fails.- It is not the most appropriate initial agent for acute, severe flares with major organ involvement requiring immediate, high-level immunosuppression.*Rituximab*- **Rituximab** (a B-cell depleting therapy) is a biologic agent usually reserved for SLE that is refractory (non-responsive) to standard induction therapies.- It is not generally recommended as the **first-line initial treatment** for a newly diagnosed major organ flare before high-dose corticosteroids and standard immunosuppressants have been utilized.
Venous thromboembolism UK Medical PG Question 8: A 35-year-old woman presents with recurrent miscarriages and thrombosis. She has positive lupus anticoagulant and anticardiolipin antibodies. What is the mechanism of thrombosis?
- A. Platelet activation
- B. Endothelial dysfunction (Correct Answer)
- C. Protein C deficiency
- D. Factor V Leiden mutation
- E. Hyperhomocysteinemia
Venous thromboembolism Explanation: ***Endothelial dysfunction***- This is the primary mechanism in **Antiphospholipid Syndrome (APS)**, where **antiphospholipid antibodies (aPL)** bind to complexes involving plasma proteins, particularly **$eta_2$-glycoprotein I**, on the endothelial surface.- This binding activates and injures the endothelium, leading to the expression of pro-coagulant factors and adhesive molecules, resulting in a systemic shift toward **thrombosis**.*Platelet activation*- While aPL antibodies do cause platelet activation and aggregation, this effect is often considered downstream or secondary to the primary interaction the antibodies have with **endothelial cells** and plasma proteins.- aPL antibodies binding to platelets via **$eta_2$-glycoprotein I** enhances the production of thromboxane A2 and promotes thrombus stabilization.*Protein C deficiency*- This is typically an inherited disorder causing decreased levels or function of the key anticoagulant Protein C, a mechanism distinct from **autoimmunity**.- Although aPL antibodies can sometimes interfere with Protein C and S function indirectly, the underlying mechanism generating the thrombotic state remains **endothelial activation**.*Factor V Leiden mutation*- This is the most common inherited thrombophilia, leading to resistance to activated **Protein C** degradation of Factor Va and VIIIa.- This inherited defect is separate from the acquired, autoimmune mechanism responsible for thrombosis in **Antiphospholipid Syndrome**.*Hyperhomocysteinemia*- Elevated **homocysteine** levels create a prothrombotic state primarily via direct cytotoxicity and oxidative stress to the **vascular endothelium**.- This condition is an independent risk factor for thrombosis and is not the pathognomonic mechanism of acquired thrombophilia defined by **lupus anticoagulant** and **anticardiolipin antibodies**.
Venous thromboembolism UK Medical PG Question 9: A 61-year-old man presents with progressive weakness in his hands and difficulty swallowing. EMG shows myopathic changes. Muscle biopsy shows rimmed vacuoles and eosinophilic inclusions. What is the most likely diagnosis?
- A. Polymyositis
- B. Dermatomyositis
- C. Inclusion body myositis (Correct Answer)
- D. Myasthenia gravis
- E. Muscular dystrophy
Venous thromboembolism Explanation: ***Inclusion body myositis*** - The combination of **progressive distal weakness** (hands) and **dysphagia**, particularly in an older man, is highly characteristic. - Definitive diagnosis relies on muscle biopsy findings of **rimmed vacuoles** and **eosinophilic inclusions**, as well as **myopathic changes** on EMG. *Polymyositis* - Typically presents with **proximal muscle weakness**, affecting hips and shoulders, rather than predominant distal hand weakness or prominent dysphagia. - Muscle biopsy shows **endomysial inflammatory infiltrates** but lacks the characteristic rimmed vacuoles or inclusions seen in IBM. *Dermatomyositis* - Shares **proximal muscle weakness** with polymyositis but is uniquely identified by specific **cutaneous manifestations** like heliotrope rash and Gottron's papules, which are not mentioned. - Muscle biopsy shows **perifascicular atrophy** and perimysial inflammation, differing from IBM's distinctive pathology. *Myasthenia gravis* - A **neuromuscular junction disorder** causing fluctuating weakness that worsens with activity, often affecting ocular, bulbar, and limb muscles. - EMG would show a **decremental response** on repetitive nerve stimulation, not primary myopathic changes, and muscle biopsy would be normal. *Muscular dystrophy* - A broad category of **genetic muscle diseases** that cause progressive weakness and myopathic changes, but the specific biopsy findings of rimmed vacuoles and eosinophilic inclusions are not typical. - Different types of muscular dystrophy have distinct genetic causes and biopsy findings (e.g., dystrophin absence in Duchenne) that do not match the features presented.
Venous thromboembolism UK Medical PG Question 10: A 52-year-old woman presents with progressive dysphagia and weight loss. She has tight skin on her face and hands. ANA shows nucleolar pattern. What is the most concerning complication to screen for?
- A. Renal crisis
- B. Pulmonary hypertension (Correct Answer)
- C. Cardiac involvement
- D. Esophageal stricture
- E. Digital ulceration
Venous thromboembolism Explanation: ***Pulmonary hypertension*** - This patient's presentation (tight skin on face/hands, dysphagia, nucleolar ANA pattern) strongly suggests **Systemic Sclerosis (SSc)**, likely the limited cutaneous form. - **Pulmonary arterial hypertension (PAH)** is a leading cause of mortality in SSc, particularly associated with the nucleolar ANA pattern (often linked to anti-U3 RNP/fibrillarin antibodies), requiring regular screening with **echocardiograms**. *Renal crisis* - **Scleroderma Renal Crisis (SRC)** involves acute onset of **malignant hypertension** and rapid kidney failure. - SRC is more commonly associated with **diffuse cutaneous SSc** and **Anti-RNA Polymerase III antibodies**, rather than the nucleolar ANA pattern. *Cardiac involvement* - Direct **cardiac involvement** (e.g., myocarditis, pericarditis, conduction defects) can occur in SSc. - While serious, **pulmonary hypertension** is statistically the most common and acutely life-threatening cardiopulmonary complication in SSc patients, making it the priority for routine screening. *Esophageal stricture* - **Dysphagia** and weight loss are highly suggestive of **esophageal dysmotility**, a nearly universal finding in SSc. - While **esophageal strictures** can occur from chronic reflux in SSc, they are a local complication, not the most concerning *systemic* or *life-threatening* complication requiring primary screening compared to PAH. *Digital ulceration* - **Digital ulcerations** are caused by severe **Raynaud's phenomenon** and microvascular ischemia, leading to pain and potential tissue loss. - Though causing significant morbidity, digital ulcerations are a peripheral manifestation and not the most acutely life-threatening *systemic* complication requiring broad mortality screening compared to **pulmonary hypertension**.
More Venous thromboembolism UK Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
